119 related articles for article (PubMed ID: 38342495)
1. Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy.
Cheng CC; Yeh HC; Su PW; Ho CL; Chang SC
Int J Hyperthermia; 2024; 41(1):2304250. PubMed ID: 38342495
[TBL] [Abstract][Full Text] [Related]
2. Nephrotoxicity and long-term survival investigations for patients with peritoneal carcinomatosis using hyperthermic intraperitoneal chemotherapy with cisplatin: A retrospective cohort study.
Ye J; Ren Y; Wei Z; Peng J; Chen C; Song W; Tan M; He Y; Yuan Y
Surg Oncol; 2018 Sep; 27(3):456-461. PubMed ID: 30217302
[TBL] [Abstract][Full Text] [Related]
3. Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.
Sin EI; Chia CS; Tan GHC; Soo KC; Teo MC
Int J Hyperthermia; 2017 Sep; 33(6):690-695. PubMed ID: 28540777
[TBL] [Abstract][Full Text] [Related]
4. Eliminating the need for preoperative intravenous hyperhydration: Sodium thiosulfate as nephrotoxicity prevention in HIPEC-treated patients - A retrospective analysis.
Vachez E; Kefleyesus A; Bakrin N; Ranchon F; Rioufol C; Vassal O; Al-Hadeedi O; Kepenekian V; Glehen O
Eur J Surg Oncol; 2024 Feb; 50(2):107955. PubMed ID: 38219699
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
6. Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases.
Steinhoff H; Acs M; Blaj S; Dank M; Herold M; Herold Z; Herzberg J; Sanchez-Velazquez P; Strate T; Szasz AM; Piso P
World J Gastroenterol; 2023 May; 29(18):2850-2863. PubMed ID: 37274066
[TBL] [Abstract][Full Text] [Related]
7. Acute Kidney Injury Following Hyperthermic Intraperitoneal Chemotherapy With Cisplatin.
Chen KL; Shamavonian R; Karpes JB; Alzahrani NA; Morris DL
Anticancer Res; 2021 Mar; 41(3):1641-1646. PubMed ID: 33788760
[TBL] [Abstract][Full Text] [Related]
8. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
[TBL] [Abstract][Full Text] [Related]
9. Incidence, risk factors, and outcomes of the transition of HIPEC-induced acute kidney injury to acute kidney disease: a retrospective study.
Lu Y; Xiao Z; Zhao X; Ye Y; Li S; Guo F; Xue H; Zhu F
Ren Fail; 2024 Dec; 46(1):2338482. PubMed ID: 38604946
[TBL] [Abstract][Full Text] [Related]
10. Risk factors of acute renal impairment after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chen CY; Chang HY; Lu CH; Chen MC; Huang TH; Lee LW; Liao YS; Chen VC; Huang WS; Ou YC; Lung FC; Wang TY
Int J Hyperthermia; 2020; 37(1):1279-1286. PubMed ID: 33198563
[TBL] [Abstract][Full Text] [Related]
11. Extensive Peritonectomy is an Independent Risk Factor for Cisplatin HIPEC-Induced Acute Kidney Injury.
Liesenfeld LF; Quiring E; Al-Saeedi M; Nusshag C; Büchler MW; Schneider M
Ann Surg Oncol; 2023 May; 30(5):2646-2656. PubMed ID: 36496489
[TBL] [Abstract][Full Text] [Related]
12. Sodium Thiosulfate Reduces Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy with Cisplatin: A Single-Center Observational Study.
Kurreck A; Gronau F; Alberto Vilchez ME; Abels W; Enghard P; Brandl A; Francis R; Föhre B; Lojewski C; Pratschke J; Thuss-Patience P; Modest D; Rau B; Feldbrügge L
Ann Surg Oncol; 2022 Jan; 29(1):152-162. PubMed ID: 34350529
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Laparoscopy in Patients With Peritoneal Carcinomatosis Is Safe and Does Not Delay Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy.
Hanna DN; Ghani MO; Hermina A; Mina A; Bailey CE; Idrees K; Magge D
Am Surg; 2022 Apr; 88(4):698-703. PubMed ID: 34732056
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in pediatric patients with peritoneal mesothelioma: a single institution experience and long term follow up.
Malekzadeh P; Good M; Hughes MS
Int J Hyperthermia; 2021; 38(1):326-331. PubMed ID: 34139940
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors.
Charrier T; Passot G; Peron J; Maurice C; Gocevska S; Quénet F; Eveno C; Pocard M; Goere D; Elias D; Ortega-Deballon P; Vaudoyer D; Cotte E; Glehen O
Ann Surg Oncol; 2016 Jul; 23(7):2315-22. PubMed ID: 26920385
[TBL] [Abstract][Full Text] [Related]
16. Development of a predictive model for risk stratification of acute kidney injury in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Krause M; Mehdipour S; Veerapong J; Baumgartner JM; Lowy AM; Gabriel RA
Sci Rep; 2024 Mar; 14(1):6630. PubMed ID: 38503776
[TBL] [Abstract][Full Text] [Related]
17. Do certain surgical steps increase postoperative morbidity after cytoreductive surgery and HIPEC- a retrospective analysis.
Riediger C; Schuster T; Bork U; Schweipert J; Sigg M; Weiss J; Weitz J
Surg Oncol; 2022 Dec; 45():101884. PubMed ID: 36347148
[TBL] [Abstract][Full Text] [Related]
18. [Construction and evaluation of a nomogram for predicting the prognosis of patients with colorectal cancer with peritoneal carcinomatosis treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
An SL; Ji ZH; Li XB; Liu G; Zhang YB; Gao C; Zhang K; Zhang XJ; Yan GJ; Yan LJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):434-441. PubMed ID: 37217351
[No Abstract] [Full Text] [Related]
19. Hyperthermic intraperitonal chemotherapy is an independent risk factor for development of acute kidney injury.
Dagel T; Misirlioglu S; Tanju S; Afsar B; Selcukbiricik F; Erus S; Vatansever D; Balik E; Taskiran C; Dilege S; Molinas Mandel N; Bugra D; Yalti T; Kanbay M
J BUON; 2018; 23(5):1528-1533. PubMed ID: 30570881
[TBL] [Abstract][Full Text] [Related]
20. Identification of risk factors associated with postoperative acute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a retrospective study.
Cata JP; Zavala AM; Van Meter A; Williams UU; Soliz J; Hernandez M; Owusu-Agyemang P
Int J Hyperthermia; 2018 Aug; 34(5):538-544. PubMed ID: 28812384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
